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Purpose: Human amniotic membrane is a highly abundant and easily
accessible tissue that may potentially be an important chondrocyte carrier
for cartilage regeneration in vivo.
Objective: Study the feasibility of cryopreserved human amniotic mem-
brane as a chondrocyte carrier for in vitro repair human articular cartilage
injuries.
Methods: Patches (6×6 cm) of cryopreserved human amniotic mem-
brane were extended into a culture dish. Then human chondrocytes
(5×105 cells) were cultured over the basal face of the amniotic membrane
for 3−4 weeks until 80−90% conﬂuence. These membranes were cut into
pieces of 0.7×0.7 cm, and each of them was placed over a chondral
defect (6mm in diameter) of osteoarthritic cartilage with the basal layer
facing the defect. The implants were cultured for 16 weeks. Evaluation
of in vitro chondrocytes culture over the human amniotic membrane and
repair, in in vitro models, of injured articular cartilage was carried out us-
ing histological (hematoxylin-eosin) and immunohistochemical (collagen
type I and II) stainings.
Results: Chondrocytes culture over the human amniotic membrane
showed that cells grown over the basal layer, but they did not proliferate
on the epithelial side. Histological techniques demonstrated that collagen
type II but not type I was expressed in the chondrocytes culture on
amniotic membrane. Valuation of repair, in 13 in vitro repair models,
showed the formation of a new tissue on OA cartilage. Integration of new
tissue with OA cartilage was excellent. Repair tissue expressed type II
collagen in 100% of experiments, however collagen type I was present in
54% of cases.
Conclusions: These results indicated that cryopreserved amniotic mem-
brane can be used as support for chondrocytes proliferation in cell therapy
to repair OA cartilage.
Support: Project funded by Servizo Galego de Sau´de (PS07/84). Silvia
Diaz Prado is beneﬁciary of an Isidro Parga Pondal contract from Xunta
de Galicia, A Coruna, Spain.
227 GLUCOSAMINE PREVENTS AND NF-kB INHIBITORS
REDUCE THE CYTOKINE-INDUCED EXPRESSION OF Il-1 IN
NORMAL HUMAN ARTICULAR CHONDROCYTES IN VITRO
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Southampton, UNITED KINGDOM
Purpose: Glucosamine (GlcN) supplements are taken by millions of
osteoarthritic (OA) patients to ameliorate their symptoms and several
large-scale studies have shown a beneﬁt in slowing the progression of
the disease. However, the molecular bases for the beneﬁcial effect of
GlcN are only beginning to be unravelled. Our aims were to determine
whether glucosamine, added to the medium of cultured non-OA chondro-
cytes, affected the cytokine-induced expression of Il-1b. In addition, we
investigated whether the NF-kB pathway is used in the signal transduction
mechanisms involved in the cytokine-induced expression of Il-1b.
Methods: Non-OA chondrocytes were isolated by sequential trypsin,
hyaluronidase and collagenase digestion from osteoporotic patients who
had sustained a fracture of the neck of femur. Previous studies had shown
that these chondrocytes are suitable control chondrocytes, because the
cells express chondrocytic genes, such as collagens types II, IX and
XI, but do not express Il-1b. Cells were maintained in MEM with 5%FCS.
Passage 2 cells were divided into the following experimental groups (n = 4
for each group): (I) control culture with no addition; (II) culture with GlcN
alone (2mM); (III) culture with TNF-a/OSM (10 ng/ml and 10m/ml) and
(IV) culture with TNF-a/OSM in presence of GlcN. In a further series,
non-OA chondrocytes were cultured with TNF-a/OSM in presence of two
compounds that inhibited the translocation of NF-kB to the nucleus. The
ﬁrst was NF-kB p65 (Ser 276) inhibitory peptide (50mM) from Imgenex,
the second was (E)-2-Fluoro-4’-methoxystilbene (0.2mM), an analogue
of Resveratrol from Merck. Media were changed twice-weekly, when the
relevant factors were also added to II, II and IV. Cells were cultured until
conﬂuency (2−3 weeks) and semi-quantitative RT-PCR was carried out.
Results: No expression of Il-1b was found in control cultures, with
GlcN alone or with the NF-kB inhibitor alone. As expected, TNF-a/OSM
induced expression of Il-1b in all cultures. However, the presence of
GlcN completed prevented the cytokine-induced expression of
Il-1b, as indicated by absence of the PCR band. Presence of the NF-
kB translocation inhibitors reduced Il-1b expression, but did not abolish it
completely, as suggested by reduced intensity of the PCR band.
Conclusions: The present studies demonstrate that glucosamine has
the capacity to inhibit the cytokine-induced expression of Il-1b. The
glucosamine effect was greater than the effect of interfering with the
NF-kB pathway of signal transduction. GlcN is a basic structural unit
of chondroitin sulphate and hyaluronan of cartilage proteoglycan aggre-
gates. Hence its beneﬁcial effects were initially suggested to be due to
stimulation of GAG synthesis, but the evidence for this mechanism is so
far limited. Other studies have shown chondroprotective effects in vitro
in that GlcN promoted the chondrogenic phenotype and inhibited MMP-
13 expression. Il-1b is thought to play a major role in the progression of
osteoarthritis, since Il-1b increases the expression of cartilage-degrading
proteases. The present study suggests that GlcN treatment may have
beneﬁcial effects through prevention of Il-1b expression, which, in turn,
might also reduce expression if its down-stream target genes. However,
these are in vitro observations and need to be conﬁrmed by in vivo
studies.
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Purpose: Glucocorticoids are therapeutic anti-inﬂammatory drugs, but
are not routinely used to treat osteoarthritis (OA) due to potential side
effects. In a proof-of-concept hand OA clinical trial, oral dosing with CRx-
102, which is a combination of the cardiovascular drug dipyridamole (Dp)
and very low-dose prednisolone (Pd), resulted in a signiﬁcant reduction
in tender and swollen joint counts, suggesting that the combination
may modify disease progression. We have previously shown that Dp
synergizes with Pd to inhibit inﬂammation in vitro and in vivo. This synergy
allows a much lower dose of Pd to be used to inhibit inﬂammation, without
the side effects associated with glucocorticoids. To determine if Dp and
Pd synergize to inhibit matrix metalloproteinase (MMP) expression, we
studied LPS-stimulated macrophages and Il-1a stimulated normal human
chondrocytes. Additionally, we evaluated the activity of the combination
on chondrocytes from human osteoarthritic joints ex vivo. The purpose
of this research was to characterize the effect of the combination of Dp
and Pd on cells and molecules relevant to the progression of OA.
Methods and Results: Transcriptional proﬁling (TP) of LPS stimulated
macrophages revealed that ADAMTS4 was up-regulated (~20-fold) in
response to LPS. Dp (10 uM) in combination with Pd (0.03 uM) inhibited
ADAMTS4 expression (67%), more than Dp (47%) or Pd (30%) alone.
MMPs 3, 10, 12, 13 and 14 were up-regulated in response to LPS, and
like ADAMTS4, were maximally inhibited by the combination of Dp and
Pd. Interestingly, analysis of supernatants from stimulated macrophages
cultured in serially diluted combinations of Pd and Dp identiﬁed strong
synergistic inhibition of MMP2 and MMP9. The MAP kinase pathway is
thought to play a role in MMP expression. Western blot analysis showed
the combination of Pd and Dp inhibited phosphorylation of p38 and JNK
but not ERK, while Pd or Dp alone did not. To further characterize the
combination on OA-relevant cell types, inhibition of MMPs and other
inﬂammatory mediators by Dp and Pd was measured in Il-1a stimulated
primary chondrocytes from normal human donors. Pd demonstrated
differential partial inhibition of MMP-3, Il-6, MCP-1 and GRO-alpha. Dp
demonstrated complete inhibition of MMP-3 and MCP-1, partial inhibition
of GRO-alpha, and no inhibition of Il-6. OA chondrocytes were isolated
from osteoarthritic joint cartilage obtained from total knee replacement
surgery, and the ability of Dp and Pd to suppress Il-1 induced production
of pro-inﬂammatory mediators including MMPs was assessed. Dp and
Pd alone and in combination suppressed production of TNFa, MIP-1a,
MIP-1b, MCP-1, RANTES, and MMP-13.
Conclusions: We show here that Pd and Dp synergize to inhibit
MMP production in macrophages and decrease expression in human
